Company Profile Corporate Governance 2012 Annual Meeting Stock Information SEC Filings Analyst Coverage Press Releases Annual Reports Investor Calendar Clinical and Scientific Calendar Board of Directors Senior Management Investor Contact Information Request Form Investor FAQ E-mail Alerts Policy on Rumors Company Profile More >> Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. More than 20 years of focused research and investment make us a leader in the NNR field. Our sci More >> Stock Quote TRGT (Common Stock) Exchange NASDAQ (US Dollar) Price $4.36 Change (%)   0.07 (1.58%) Volume 288,879 Data as of 05/16/12 4:00 p.m. ET Minimum 20 minute delay Refresh quote Recent News More News >> Date Title   05/03/12 Targacept Reports First Quarter 2012 Financial Results 04/25/12 Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline 04/24/12 Targacept to Report First Quarter 2012 Financial Results on May 3, 2012 Contact Information Alan Musso Senior Vice President and Chief Financial Officer Phone: (336) 480-2186 Fax: (336) 480-2103 E-mail: alan.musso@targacept.com Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ©2011 Targacept, Inc.Terms of Use HomeDirectionsContactSite Map Go